Department of Pharmacology & Toxicology, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada.
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON M4G 3M5, Canada.
Curr Oncol. 2023 Sep 18;30(9):8550-8562. doi: 10.3390/curroncol30090620.
Concurrent cohorts of 644,932 women aged 50-74 screened annually due to family history, dense breasts or biennially in the Ontario Breast Screening Program (OBSP) from 2011-2014 were linked to provincial administrative datasets to determine health system resource utilization and costs. Age-adjusted mean and median total healthcare costs (2018 CAD) and incremental cost differences were calculated by screening outcome and compared by recommendation using regression models. Healthcare costs were compared overall and 1 year after a false positive (n = 46,081) screening mammogram and 2 years after a breast cancer diagnosis (n = 6011). Mean overall healthcare costs by age were highest for those 60-74, particularly with annual screening for family/personal history (CAD 5425; 95% CI: 5308 to 5557) compared to biennial. Although the mean incremental cost difference was higher (23.4%) by CAD 10,235 (95% CI: 6141 to 14,329) per breast cancer for women screened annually for density ≥ 75% compared to biennially, the cost difference was 12.0% lower (-CAD 461; 95% CI: -777 to -114) per false positive result. In contrast, for women screened annually for family/personal history, the mean cost difference per false positive was 19.7% higher than for biennially (CAD 758; 95% CI: 404 to 1118); however, the cost difference per breast cancer was only slightly higher (2.5%) by CAD 1093 (95% CI: -1337 to CAD 3760). Understanding that associated costs of annual compared to biennial screening may balance out by age and outcome can assist decision-making regarding the use of limited healthcare resources.
2011 年至 2014 年期间,共有 644932 名年龄在 50-74 岁的女性因家族史、致密乳房或每两年一次的安大略省乳房筛查计划(OBSP)接受年度筛查,将这些女性的信息与省级行政数据集相联系,以确定卫生系统资源的利用和成本。根据筛查结果计算了调整年龄后的平均和中位总医疗保健费用(2018 加元)和增量成本差异,并使用回归模型按推荐意见进行了比较。对整体医疗保健费用以及假阳性(n=46081)筛查乳房 X 光照片后 1 年和乳腺癌诊断后 2 年(n=6011)进行了比较。按年龄划分,年龄在 60-74 岁之间的女性总体医疗保健费用最高,尤其是每年因家族/个人病史接受筛查的女性(CAD5425;95%CI:5308 至 5557)比每两年筛查一次的费用高。尽管每例乳腺癌的增量成本差异(CAD10235;95%CI:6141 至 14329)高 23.4%,但与每两年筛查一次相比,每年因致密性≥75%接受筛查的女性成本差异低 12.0%(-CAD461;95%CI:-777 至-114)。相比之下,对于每年因家族/个人病史接受筛查的女性,每例假阳性结果的平均成本差异比每两年筛查一次高 19.7%(CAD758;95%CI:404 至 1118);然而,每例乳腺癌的成本差异仅略高(CAD1093;95%CI:-1337 至 CAD3760),高 2.5%。了解与每两年筛查相比,年度筛查的相关成本可能会因年龄和结果而平衡,可以帮助决策者合理利用有限的医疗保健资源。